Albireo

Arvid Wallgrens Backe 20
413 46 Gothenburg
Gothenburg
413 46

Tel: 46-31-7411480
Fax: 46-31-820223

Show jobs for this employer

68 articles with Albireo

  • Albireo Pharma, Inc., a clinical-stage rare liver disease company developing novel bile acid modulators, announced the grant of inducement stock options exercisable for an aggregate of 18,500 shares of Albireo’s common stock.

  • – Appointment strengthens leadership team as the Company readies for potential global odevixibat launch and progresses multiple clinical development programs – – Deep experience spanning drug development, manufacturing, quality and supply chain

  • Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced participation in the upcoming Needham 20th Annual Healthcare Conference on April 12-15.

  • – Dosed first patients in Phase 1 study with new product candidate A3907 – – First patient dosed in ASSERT global Phase 3 study of odevixibat for Alagille syndrome –

  • - Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that it will host a virtual Commercial Day for investors on February 11 from 11:30-1:00pm EST. Presentations will include an overview of the long-term corporate strategy, the global market opportunity in rare pediatric and adult liver disease, and the global commercialization strategy and launch readiness plans for o

  • Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will participate in the H.C. Wainwright Virtual BioConnect 2021 Conference to be held January 11-14, 2021 and the LifeSci Advisors 10th Annual Corporate Access Event to be held January 6-14, 2021. The virtual LifeSci Advisors event presentation will be live at 1

  • Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 18,500 shares of Albireo’s common stock. The stock options are exercisable at a price of $39.77 per share, the closing price of Albireo’s common stock on December 9, 2020, the grant date, and were granted as inducements material to the em

  • - PEDFIC 1 meets both U . S . and EU primary and secondary endpoints with high ly statistically significant reductions in serum bile acids and pruritus - - Interim results from long-term extension study show sustained improvements in serum bile acids, pruritus - - Improvements in growth measures and liver parameters observed with long-term administration suggests disease modifying potential of odevixibat - -

  • Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present via webcast at the 2020 Jefferies London Healthcare Conference on November 19 at 12 p.m. EST. The Company will also be participating in the virtual Piper Sandler 32nd Annual Healthcare Conference being held December 1-3. A live audio webcast of the

  • - P ositive P hase 3 d ata for o devixibat in PFIC with filings on track for no later than early 202 1 - - Phase 3 PFIC data accepted as late breakers at upcoming AASLD Meeting - - Introduces new and novel bile acid modulator A3907 at AASLD - - Raised $160 million in gross proceeds in public offering of 4,000,000 shares - - Company to host post-AASLD Business Update Call on Tuesday, November 17, 2020 -

  • - Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, joins the PFIC Advocacy and Resource Network (PFIC Network) in recognition of PFIC Awareness Day 2020, a global effort to support patients and families affected by progressive familial intrahepatic cholestasis (PFIC). PFIC is a rare genetic disorder that causes progressive, life-threatening liver disease characterized by a

  • Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 23,000 shares of Albireo’s common stock. The stock options are exercisable at a price of $32.90 per share, the closing price of Albireo’s common stock on September 28, 2020, the grant date, and were granted as inducements material to the

  • Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced positive topline results from PEDFIC 1, a global Phase 3 clinical trial evaluating the efficacy and safety of odevixibat and the largest study ever conducted in PFIC1 and PFIC2.

  • ‒ Achieved primary endpoint ‒ ‒ Unremarkable results in key NASH measures ‒ ‒ Company discontinuing further development ‒

  • — Completed last patient visits in Phase 3 PFIC and Phase 2 NASH Trials — —  Enrolled first biliary atresia patients in second odevixibat pivotal study — —  Completed two financing transactions to secure cash into beginning of 2022 — —  Management to host conference call and webcast today at 10:00 a.m. ET — BOSTON, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today pro

  • Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 10:00 a.m. ET on August 6, 2020, to provide a business update and review the company’s financial results for the second quarter ended June 30, 2020. To access the live c

  • Albireo Pharma, Inc. announced that Ron Cooper, President and Chief Executive Officer, will participate in a fireside chat presentation at the virtual William Blair Biotech Focus Conference 2020 on Thursday, August 6, at 2 p.m. EDT.

  •  Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the first patient has been enrolled in the BOLD ( B iliary atresia and the use of O devixibat in treating L iver D isease) global Phase 3

  • — Restructured HealthCare Royalty Partners elobixibat royalty monetization agreement nets additional $15M in non-dilutive capital —   — Initial draw down of $10M on debt facility of up to $80M with Hercules Capital —

  • Albireo, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today provided a business update and reported financial results for the first quarter ended March 31, 2020.